Cytokinetics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
The current Cytokinetics(CYTK) stock price is $60.16, with a market capitalization of 7.35B. The stock trades at a price-to-earnings (P/E) ratio of -9.54.
On 2025-11-08, Cytokinetics(CYTK) stock traded between a low of $58.25 and a high of $60.36. Shares are currently priced at $60.16, which is +3.3% above the low and -0.3% below the high.
Cytokinetics(CYTK) shares are trading with a volume of 1.84M, against a daily average of 1.78M.
During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $64.13 at its peak.
During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $64.13 at its peak.
CYTK News
Cytokinetics recently reported its third quarter 2025 earnings, highlighting revenue growth to US$1.94 million but a substantially widened net loss of US$306.18...
A class action lawsuit was filed against Cytokinetics, Inc. (CYTK) on September 17, 2025. The plaintiffs (shareholders) alleged that they bought CYTK stock at a...
Cytokinetics ((CYTK)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst...
Analyst ratings
81%
of 21 ratingsMore CYTK News
Analyst Maxwell Skor of Morgan Stanley maintained a Buy rating on Cytokinetics, retaining the price target of $65.00. Meet Your ETF AI Analyst Discover how TipR...
Jason Zemansky, an analyst from Bank of America Securities, reiterated the Hold rating on Cytokinetics. The associated price target was raised to $63.00. Meet Y...
Earnings Call Insights Cytokinetics outlines aficamten U.S. and EU launch plans with $1.2B in cash as FDA decision nears Nov. 06, 2025 4:46 AM ET Cytokinetics,...
Reports Q3 revenue $1.94M, consensus $6.05M. The net loss for the third quarter of 2025 includes the debt conversion expense of $121.2M due to the induced excha...
Investors in Cytokinetics (CYTK) are reacting after news surfaced of a class action lawsuit claiming the company misrepresented key aspects of its aficamten dru...
JPMorgan raised the firm’s price target on Cytokinetics (CYTK) to $70 from $55 and keeps an Overweight rating on the shares. The firm upped the price target aft...